Navigation Links
Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
Date:6/22/2011

NUTLEY, N.J. and BASEL, Switzerland, June 22, 2011 /PRNewswire/ -- The Roche manuscript: "Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies" has been published in the prestigious Proceedings of the National Academy of Sciences of the USA (PNAS). Corresponding authors are Wolfgang Schaefer, Research Leader Molecular Biology in Biologics Research at Penzberg, and Christian Klein, Head of Oncology Programs, Discovery Oncology at Roche Glycart. Both are part of Roche's Pharma Research and Early Development (pRED) organization.  

"It is encouraging to us that PNAS reviewers recognized the novelty of the approach for the generation of human bispecific, bivalent antibodies," note Wolfgang Schaefer and Christian Klein. "This technological breakthrough from pRED allowing generation and production of bispecific bivalent IgG antibodies that are very similar to conventional IgGs will prove a formidable benefit to patients."

The published paper describes a novel and generic approach to convert two given antibodies to human bivalent bispecific IgG antibodies that behave like standard monoclonal IgG antibodies in terms of target binding, stability and pharmacokinetics.

"Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies", PNAS online Early Edition (EE), http://www.pnas.org/content/early/recent.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
2. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
3. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
4. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
5. Ikaria® To Present at 2011 BIO Business Forum and International Convention
6. Most Expensive Teas in the World Worth US$44,500 per 4 Ounces Each are Positioned for International Distribution Says Protein Reactor Combined Fuels Inc (OTC: PRCF) Founder Chairman and CEO Nestor C. Buenaflor
7. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
8. Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes
9. MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C.
10. NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
11. BioXpress Therapeutics SA to Partner the 2011 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...  Vyriad Inc. announced today the appointment of ... Directors. "We are delighted to welcome Al ... develop our oncolytic viruses as the next generation of ... , MD, PhD, CEO of Vyriad. "Al and his ... passion for making a difference for cancer patients—their philanthropy ...
(Date:12/7/2016)... Texas , Dec. 7, 2016  Genprex, ... of revolutionary immunogene therapy treatments, today announced that ... practice within a leading strategic communications and advisory ... communications program. The program will combine investor relations, ... objective of raising the profile of Genprex and ...
(Date:12/7/2016)... BOULDER, Colo. , Dec. 7, 2016  Muse ... genome engineering technologies, today announced that Dr. Kevin ... member of the Board of Directors. ... , who becomes the company,s Chief Science Officer as ... and Executive Director of the BioDesign Center at the ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, 2016 /PRNewswire/ ... immune modulatory medicines, announced today the initiation of a ... candidate, LYC-30937- E nteric C oated, in patients ... that is estimated to affect as many as 7.5 million ... with approximately 1.5 - 3 million cases being diagnosed ...
Breaking Biology Technology:
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):